At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 441 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Overweight and Obesity. Completed, enrolled 441 participants across 20 sites.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight, Obesity
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
Enrollment StartSep 2023
First PostedSep 2023
Primary CompletionJan 2026
TodayJul 2026
First PostedSep 21, 2023
Enrollment StartSep 20, 2023
Primary CompletionJan 20, 2026
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 2.8 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC